Status:
COMPLETED
High-dose Antioxidants for Central Serous Chorioretinopathy
Lead Sponsor:
Prince of Songkla University
Collaborating Sponsors:
Alcon Research
Conditions:
Central Serous Chorioretinopathy
Eligibility:
All Genders
30-50 years
Phase:
PHASE2
Brief Summary
Central serous chorioretinopathy (CSC) is the serous neurosensory detachment that usually involves the macular area. It is common in patients between 30-50 years old and effects male more often than f...
Eligibility Criteria
Inclusion
- patients with acute central serous chorioretinopathy within 6 weeks of onset
- age between 30-50 years
- new or recurrent attack (the symptom-free period should longer than 6 months)
- fluorescein angiography (FA) confirmed the diagnosis with the inkblot or smoke-stack leakage and the optical coherence tomography (OCT) showed definite subretinal fluid
- patients' ability for proper follow up.
Exclusion
- chronic central serous chorioretinopathy(longer than 6 weeks)
- complicated central serous chorioretinopathy such as secondary choroidal neovascularization (CNV) that detected from FA
- pregnancy, steroid user and patients that contraindicated for high dose antioxidants therapy such as heavy smokers, lung cancer, thyrotoxicosis, renal stone and anemia (hematocrit less than 30%).
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00963131
Start Date
December 1 2004
End Date
June 1 2009
Last Update
December 30 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Ophthalmology, Faculty of medicine, Prince of Songkla university
Hat Yai, Changwat Songkhla, Thailand, 90110